CN Patent

CN103923000A — 几种新晶型及其制备方法

Assigned to Crystal Pharmatech Co Ltd · Expires 2014-07-16 · 12y expired

What this patent protects

本发明提供4-[4-({[4-氯-3-(三氟甲基)苯基)]氨基甲酰基}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺的晶型A、晶型B、晶型C、晶型D和晶型II及其制备方法。本发明提供的几种新晶型可用于治疗多种病症，特别是可用于治疗晚期直肠癌的病症。

USPTO Abstract

本发明提供4-[4-({[4-氯-3-(三氟甲基)苯基)]氨基甲酰基}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺的晶型A、晶型B、晶型C、晶型D和晶型II及其制备方法。本发明提供的几种新晶型可用于治疗多种病症，特别是可用于治疗晚期直肠癌的病症。

Drugs covered by this patent

chembl-chembl1946170 (REGORAFENIB)

Patent Metadata

Patent number: CN103923000A
Jurisdiction: CN
Classification: —
Expires: 2014-07-16
Drug substance claim: No
Drug product claim: No
Assignee: Crystal Pharmatech Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.